Mark Schneyer Sells 3,506 Shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) EVP Mark Schneyer sold 3,506 shares of the stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $21.79, for a total value of $76,395.74. Following the transaction, the executive vice president directly owned 66,145 shares of the company’s stock, valued at $1,441,299.55. The trade was a 5.03% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

ACADIA Pharmaceuticals Price Performance

Shares of ACADIA Pharmaceuticals stock opened at $21.48 on Thursday. The business has a 50 day simple moving average of $22.10 and a two-hundred day simple moving average of $23.89. ACADIA Pharmaceuticals Inc. has a 12 month low of $14.45 and a 12 month high of $28.35. The stock has a market capitalization of $3.68 billion, a P/E ratio of 9.38, a PEG ratio of 23.31 and a beta of 0.86.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.02). ACADIA Pharmaceuticals had a net margin of 36.49% and a return on equity of 12.49%. The firm had revenue of $268.10 million for the quarter, compared to analyst estimates of $280.25 million. During the same period in the previous year, the company earned $0.11 EPS. ACADIA Pharmaceuticals’s revenue was up 9.7% compared to the same quarter last year. As a group, research analysts anticipate that ACADIA Pharmaceuticals Inc. will post 0.45 EPS for the current fiscal year.

Trending Headlines about ACADIA Pharmaceuticals

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: Strong early adoption of DAYBUE — management highlighted DAYBUE STIX generated $101 million in Q1, helping total revenue and supporting the company’s confidence in the U.S. launch. Read More.
• Positive Sentiment: Full-year guidance reaffirmed — ACAD reaffirmed its 2026 financial guidance and reiterated revenue targets (management indicated confidence in the year despite the quarter). That reduces concern about an earnings-only miss being a broader slowdown. Read More.
• Neutral Sentiment: Company materials posted — management released a press release and slide deck for the quarter; investors should review slides for product/unit trends and margin commentary. Read More.
• Negative Sentiment: Earnings and revenue miss — ACAD reported $0.02 EPS vs. consensus ~$0.04 and revenue $268.1M vs. ~$280.3M, which sparked selling pressure as a headline miss despite solid margins. Read More.
• Negative Sentiment: Insider selling — two insiders (EVP Mark Schneyer and James Kihara) disclosed sales on May 4th, which can weigh on sentiment even if sales are routine. Read More.

Wall Street Analysts Forecast Growth

ACAD has been the subject of a number of research analyst reports. Wall Street Zen cut ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, January 31st. Oppenheimer restated a “market perform” rating on shares of ACADIA Pharmaceuticals in a research report on Friday, February 6th. Royal Bank Of Canada dropped their price target on ACADIA Pharmaceuticals from $31.00 to $30.00 and set an “outperform” rating for the company in a research report on Thursday, February 26th. TD Cowen upped their price target on ACADIA Pharmaceuticals from $35.00 to $37.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Finally, Wolfe Research initiated coverage on ACADIA Pharmaceuticals in a research report on Monday, February 23rd. They issued an “outperform” rating and a $33.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $31.21.

Hedge Funds Weigh In On ACADIA Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. Braidwell LP acquired a new stake in ACADIA Pharmaceuticals during the third quarter worth $50,760,000. Norges Bank acquired a new stake in ACADIA Pharmaceuticals during the fourth quarter worth $40,266,000. Millennium Management LLC increased its stake in ACADIA Pharmaceuticals by 2,052.1% during the third quarter. Millennium Management LLC now owns 1,483,235 shares of the biopharmaceutical company’s stock worth $31,652,000 after acquiring an additional 1,414,315 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its stake in ACADIA Pharmaceuticals by 390.1% during the third quarter. Arrowstreet Capital Limited Partnership now owns 1,648,864 shares of the biopharmaceutical company’s stock worth $35,187,000 after acquiring an additional 1,312,426 shares during the last quarter. Finally, Logos Global Management LP acquired a new stake in ACADIA Pharmaceuticals during the fourth quarter worth $22,704,000. 96.71% of the stock is currently owned by institutional investors and hedge funds.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.